Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-s…

Overview of attention for article published in BMC Cancer, April 2019

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (65th percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

policy: 1 policy source
twitter: 1 X user

reddit: 1 Redditor

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 56 Mendeley

Summary Policy documents X Reddit Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

nivolumab

Cited by Canadian Agency for Drugs and Technologies in Health on 11 Jul 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.